Beijing Tiantan Biological Products Co., Ltd.

Shanghai Stock Exchange 600161.SS

Beijing Tiantan Biological Products Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 7.82%

Beijing Tiantan Biological Products Co., Ltd. Return on Assets (ROA) is 7.82% for the year ending December 31, 2023, a -15.98% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Beijing Tiantan Biological Products Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was 9.31%, a 0.85% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 9.23%, a -26.18% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 12.51%, a -11.69% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 14.16%, a 40.85% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shanghai Stock Exchange: 600161.SS

Beijing Tiantan Biological Products Co., Ltd.

CEO	Mr. Dao Xing Fu
IPO Date	June 16, 1998
Location	China
Headquarters	No. 2 Courtyard
Employees	4,858
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Consumer Packaged Goods Meat Personal Care Pharmaceuticals Plastics Vaccines

Description

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.

Key trends

Past 5 years